Eikelboom JW, Lonn E, Genest J Jr, et al.- Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med, 1999, 131, 363-375.
Genest J, Audelin MC, Loon E.- Homocysteine: to screen and treat or to wait and see? CMAJ, 2000, 163, 37-38.
Pearson TA.- New tools for coronary risk assessment: what are their advantages and limitations? Circulation, 2002, 105, 886-892.
Buysschaert M.- L'homocystéine: un paramètre à suivre? Journal du médecin (Belgique), 2004, n°1563.
Nicolas J-P, Chango A.- Dérégulation du métabolisme de l'homocystéine et conséquences pour le système vasculaire. Bull Acad Natle Méd, 1997, 181, 313-331.
Causé E, Candito M, Charpiot P, et al.- Journée nationale homocystéine Toulouse, 21 septembre 2001. Ann Biol Clin, 2001, 59, 339-353.
Stanger O, Herrmann W, Pietrzik K, et al.- German, Austrian and Swiss Homocysteine Society: Consensus Paper on the rational Clinical Use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases - Guidelines and Recommendations. Clin Chem Lab Med, 2003, 41, 1392-1403.
Chango A, Potier De Courcy G, et al.- 5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohort. Br J Nutr, 2000, 84, 891-896.
Conri C, Constans J, Parrot F, et al.- Homocystéinémie: rôle en pathologie vasculaire. La Presse Médicale, 2000, 29, 737-741.
Guilland J-C, Favier A, Potier de Courcy G, et al.- L'hyperhomocystéinémie: facteur de risque ou simple marqueur? Pathologie & Biologie, 2003, 51, 101-110.
Refsum H, Smith AD, Ueland PM, et al.- Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem, 2004, 50, 3-32.
McCully KS.- Vascular pathology of homocystéinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol, 1969, 56, 111-112.
Wilcken DEL, Wilcken B.- The pathogenesis of coronary artery desease: a possible role for the methionine metabolism. J Clin Invest, 1976, 57, 1079-1082.
Stampfer MJ, Malinow MR, Willet WC, et al.- A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA, 1992, 7, 877-881.
Nygard O, Nordrehaug JE, Refsum H, et al.- Plasma homocysteine levels and mortality in patients with coronary artery disease. NEMJ, 1997, 337, 230-236.
Den Heijer M, Koster T, Blom HJ, and al.- Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl Med J, 1996, 334, 759-762.
Boushey CJ, Beresford SA, Omenn GS, et al.- A quantitative assessment of plasma homocysteine as a factor for vascular disease. Probable benefits of increasing folic acide intakes. JAMA, 1995, 274, 1049-1057.
The homocysteine Studies Collaboration.- Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 2002, 288, 2015-2022.
Wald DS, Law M, Morris JK.- Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ, 2002, 325, 1202-1206
Kuo HK, Sorond FA, Chen JH, et al.- The role of homocysteine in multisystem age-related problems: a systematic review. J Gerontol A Biol Sci Med Sci, 2005, 60, 1190-1201.
Cacoub P, Gatel A, Sbai A, et al.- Hyperhomocystéinémie, athérosclérose et thromboses artérielles et veineuses. Ann Méd Interne, 1996, 147, 352-360
Clarke R, den Heijer M, Sherliker P, et al.- Homocysteine and risk of cardiovascular disease and venous thrombosis, in Arnout J, de Gaetano G, Hoylaerts M, Peerlinck K, Van Geet C, Verhaeghe R. Ed., Thrombosis. Fundamental and clinical aspects. Leuven University Press, Leuven, 2003, 353-370
Beaudeux J-L, Jacob N, Giral P, et al.- Nouveaux marqueurs biologiques non lipidiques de l'athérosclérose. Ann Med Interne, 2001, 152, 169-179.
David J-L.- L'hyperhomocystéinémie, facteur du risque thrombo-embolique veineux. Louvain Méd, 2000, 119, 191-196.
Booth GL, Wang EE, and the Canadian Task Force on Preventive Health Care.- Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. CMAJ, 2000, 163, 21-29.
Chamberlain KL.- Homocysteine and cardiovascular disease: a review of current recommendations for screening and treatment. J Am Acad Nurse Pract, 2005, 17 90-95.
Malinow R, Duell P, Hess D et al.- Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patient with coronary disease. NEMJ, 1998, 338, 1009-1015.
Tice JA, Ross E, Coxson PG, et al.- Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA, 2001, 286, 936-943.
Blacher J, Safar M.- Y a-t-il une place pour la thérapeutique de l'hyperhomocystéinémie? Médecine Thérapeutique Endocrinologie et Reproduction, 2001, 3, 358-363
Hankey GJ, Eikelboom JW, Ho WK, van Bockxmeer FM.- Clinical usefulness of plasma homocysteine in vascular disease. Med J Aust, 2004, 181, 314-318.
Moat SJ, Lang D, McDowell IF, et al.- Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem, 2004, 15, 64-79.
Peterson JC, Spence JD.- Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet, 1998, 351, 263.
Hackam DG, Peterson JC, Spence JD.- What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens, 2000, 13, 105-110.
Vermeulen EGJ, Stehouwer CDA, Twisk JWR, et al.- Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet, 2000, 355, 517-522.
Schnyder G, Roffi M, Flammer Y, et al.- Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA, 2002, 288, 973-979.
Lange H, Suryapranata H, De Luca G, et al.- Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med, 2004, 350, 2673-2681.
Gottlieb S.- Reducing homocysteine levels does not prevent stroke recurrence. JAMA, 2004, 291, 621-622.
Toole JF, Malinow MR, Chambless LE, et al.- Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA, 2004, 291, 565-575.
Spence JD.- Homocysteine: call off the funeral. Stroke, 2006, 37, 282-283.
Spence JD, Cordy P, Kortas C, Freeman D.- Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol, 1999, 19, 405-410.
Bonaa KH, Njolstad I, Ueland PM, et al.- Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med, 2006, 354, 1578-1588.
The Heart Outcome Prevention Evaluation (HOPE) 2 Investigators.- Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med, 2006, 354, 1567-1577.
Loscalzo J.- Homocysteine trials - Clear outcomes for complex reasons. N Engl J Med, 2006, 354, 1629-1632.
Genest J Jr.- Emerging risk factors associated with cardiovascular diseases. Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases. Can J Cardiol, 1999, 15, 73G-76G
Malinow MR, Bostom AG, Krauss RM.- Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation, 1999, 99, 178-182.
O'Callaghan P, Ward D, Graham I.- Homocysteine and cardiovascular disease: time to routinely screen and treat? Br J Cardiol, 2003, 10, 115-117
Ubbink JB, Van der Merwe A, Vermaak WJ, Delport R. - Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig, 1993, 71, 993-998.
Cuskelly GJ, McNulty H, Scott JM.- Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects. Lancet, 1996, 347, 657-659
Lichtenstein AH, Russell RM.- Essential nutrients: food or supplements? Where should the emphasis be? JAMA, 2005, 20, 351-358.
Paquot N, Scheen AJ.- La place des micronutriments en médecine. Rev Med Liège, 2006, 61, 464-470.
Eichholzer M, Tonz O, Zimmermann R.- Folic acid: a public-health challenge. Lancet, 2006, 367, 1352-136.
Czernichow S, Blacher J, Arveiler D, Ducimetiere P.- Prévention nutritionnelle par les vitamines B: vers un programme-pilote d'enrichissement des farines en France. Cah Nutr Diét, 2004, 1-6.
